Three-year outcomes of the randomized phase III SEIPLUS trial of extensive intraoperative peritoneal lavage for locally advanced gastric cancer

Jing Guo, Aman Xu, Xiaowei Sun, Xuhui Zhao, Yabin Xia, Huamin Rao, Yaming Zhang, Rupeng Zhang, Li Chen, Tao Zhang, Gang Li, Hongtao Xu, Dazhi Xu, Jing Guo, Aman Xu, Xiaowei Sun, Xuhui Zhao, Yabin Xia, Huamin Rao, Yaming Zhang, Rupeng Zhang, Li Chen, Tao Zhang, Gang Li, Hongtao Xu, Dazhi Xu

Abstract

Whether extensive intraoperative peritoneal lavage (EIPL) after gastrectomy is beneficial to patients with locally advanced gastric cancer (AGC) is not clear. This phase 3, multicenter, parallel-group, prospective randomized study (NCT02745509) recruits patients between April 2016 and November 2017. Eligible patients who had been histologically proven AGC with T3/4NxM0 stage are randomly assigned (1:1) to either surgery alone or surgery plus EIPL. The results of the two groups are analyzed in the intent-to-treat population. A total of 662 patients with AGC (329 patients in the surgery alone group, and 333 in the surgery plus EIPL group) are included in the study. The primary endpoint is 3-year overall survival (OS). The secondary endpoints include 3-year disease free survival (DFS), 3-year peritoneal recurrence-free survival (reported in this manuscript) and 30-day postoperative complication and mortality (previously reported). The trial meets pre-specified endpoints. Estimated 3-year OS rates are 68.5% in the surgery alone group and 70.6% in the surgery plus EIPL group (log-rank p = 0.77). 3-year DFS rates are 61.2% in the surgery alone group and 66.0% in the surgery plus EIPL group (log-rank p = 0.24). The pattern of disease recurrence is similar in the two groups. In conclusion, EIPL does not improve the 3-year survival rate in AGC patients.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s).

Figures

Fig. 1. Trial CONSORT flow diagram.
Fig. 1. Trial CONSORT flow diagram.
EIPL extensive intraoperative peritoneal lavage.
Fig. 2. Kaplan–Meier estimates of survival curves…
Fig. 2. Kaplan–Meier estimates of survival curves for the surgery alone and surgery+EIPL groups.
Kaplan–Meier estimates of overall survival (a), disease-free survival (b), and peritoneal recurrence-free survival (c) in all randomized patients by treatment group. Log-rank test was used to compare both curves. EIPL extensive intraoperative peritoneal lavage.
Fig. 3. Subgroup analyses.
Fig. 3. Subgroup analyses.
a Subgroup analyses of overall survival according to the clinicopathological characteristics of the patients (n = 662). Data are plotted as HR value (red squares) with the corresponding two-sided 95% CI (error bars) based on the Cox regression method. b, c Kaplan–Meier estimates of overall survival (b) and disease-free survival (c) in stage N1 patients by treatment group. Log-rank test was used to compare both curves. EIPL extensive intraoperative peritoneal lavage, OS overall survival, HR hazard ratio, 95% CI 95% confidence interval, BMI body mass index.

References

    1. Bonenkamp JJ, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345:745–748. doi: 10.1016/S0140-6736(95)90637-1.
    1. Zhang J, et al. Evaluation of the seventh AJCC TNM staging system for gastric cancer: a meta-analysis of cohort studies. Tumour Biol. 2014;35:8525–8532. doi: 10.1007/s13277-014-1848-6.
    1. Kuramoto M, et al. A proposal of a practical and optimal prophylactic strategy for peritoneal recurrence. J. Oncol. 2012;2012:340380. doi: 10.1155/2012/340380.
    1. D’Angelica M, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann. Surg. 2004;240:808–816. doi: 10.1097/01.sla.0000143245.28656.15.
    1. Hirao M, et al. Long-term outcomes after prophylactic bursectomy in patients with resectable gastric cancer: final analysis of a multicenter randomized controlled trial. Surgery. 2015;157:1099–1105. doi: 10.1016/j.surg.2014.12.024.
    1. Fuchs CS, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:420–435. doi: 10.1016/S1470-2045(18)30791-5.
    1. Yonemura Y, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur. J. Surg. Oncol. 2010;36:1131–1138. doi: 10.1016/j.ejso.2010.09.006.
    1. Kasagi Y, et al. Peritoneal dissemination requires an Sp1-dependent CXCR4/CXCL12 signaling axis and extracellular matrix-directed spheroid formation. Cancer Res. 2016;76:347–357. doi: 10.1158/0008-5472.CAN-15-1563.
    1. Han TS, et al. Dissemination of free cancer cells from the gastric lumen and from perigastric lymphovascular pedicles during radical gastric cancer surgery. Ann. Surg. Oncol. 2011;18:2818–2825. doi: 10.1245/s10434-011-1620-8.
    1. Marutsuka T, et al. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin. Cancer Res. 2003;9:678–685.
    1. Masuda T, et al. The effect of extensive intraoperative peritoneal lavage therapy (EIPL) on stage III B + C and cytology-positive gastric cancer patients. Int. J. Clin. Oncol. 2016;21:289–294. doi: 10.1007/s10147-015-0892-6.
    1. Kuramoto M, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann. Surg. 2009;250:242–246. doi: 10.1097/SLA.0b013e3181b0c80e.
    1. Kim G, et al. Extensive peritoneal lavage after curative gastrectomy for gastric cancer (EXPEL): study protocol of an international multicentre randomised controlled trial. Jpn. J. Clin. Oncol. 2017;47:179–184. doi: 10.1093/jjco/hyw153.
    1. Misawa K, et al. Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial) Br. J. Surg. 2019;106:1602–1610. doi: 10.1002/bjs.11303.
    1. Batista TP, Martins MR, Martins-Filho ED, Santos RL. A phase II trial exploring the extensive intra-operative peritoneal lavage (EIPL) as a prophylactic strategy for peritoneal recurrence in locally advanced gastric cancer: reporting postoperative morbidity and mortality after early closure. Arquivos Gastroenterol. 2015;52:161–164. doi: 10.1590/S0004-28032015000200017.
    1. Guo J, et al. Combined surgery and extensive intraoperative peritoneal lavage vs surgery alone for treatment of locally advanced gastric cancer: The SEIPLUS Randomized Clinical Trial. JAMA Surg. 2019;154:610–616. doi: 10.1001/jamasurg.2019.0153.
    1. Kim SJ, et al. Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology. 2009;253:407–415. doi: 10.1148/radiol.2532082272.
    1. Wang C, et al. The predictive and prognostic value of early metabolic response assessed by positron emission tomography in advanced gastric cancer treated with chemotherapy. Clin. Cancer Res. 2016;22:1603–1610. doi: 10.1158/1078-0432.CCR-14-3235.
    1. Nie RC, et al. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. Eur. J. Cancer. 2019;106:1–11. doi: 10.1016/j.ejca.2018.10.011.
    1. Sakuramoto S, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 2007;357:1810–1820. doi: 10.1056/NEJMoa072252.
    1. Sasako M, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 2011;29:4387–4393. doi: 10.1200/JCO.2011.36.5908.
    1. Sasako M, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N. Engl. J. Med. 2008;359:453–462. doi: 10.1056/NEJMoa0707035.
    1. Noh SH, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–1396. doi: 10.1016/S1470-2045(14)70473-5.
    1. Kodera Y, et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J. Surg. Oncol. 1999;72:60–64. doi: 10.1002/(SICI)1096-9098(199910)72:2<60::AID-JSO3>;2-1.
    1. Yang HK, et al. Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial. Lancet Gastroenterol. Hepatol. 2021;6:120–127. doi: 10.1016/S2468-1253(20)30315-0.
    1. Bohon C, Welch H. Quadratic relations of BMI with depression and brain volume in children: analysis of data from the ABCD study. J. Psychiatr. Res. 2021;136:421–427. doi: 10.1016/j.jpsychires.2021.02.038.
    1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 2010;17:1471–1474. doi: 10.1245/s10434-010-0985-4.
    1. Kim JH, Lee HH, Seo HS, Jung YJ, Park CH. Borrmann type 1 cancer is associated with a high recurrence rate in locally advanced gastric cancer. Ann. Surg. Oncol. 2018;25:2044–2052. doi: 10.1245/s10434-018-6509-3.
    1. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 14, 113–123 (2011).

Source: PubMed

3
Iratkozz fel